peter holk nielsen is joining us for a first on interview on these earnings mr.lsen, thank you for joining us this morning. now, you reported organic sales growth down 4% with a down quarter negative sales goet in every dwigs division except technical and pharma not a surprise given the guidance you gave the market earlier this year, but you have narrowed your sales growth outlook for the rye mander erme of the year. >> good morning to you, firly. >> the u.s. bioethnatural business has been, first of all, impacted by a general slowdown actually, not in demand, but in output of ethnatural, and then the last two weeks of march. >> all these businesses that are related to bioenergy has been affected by these things that has taken us by surprise. that is really the main deviation from what we said in january. that's all about u.s. bioethanol. sfwhoo can we with expect to see a turnaround >> we're not expecting it. what we are calling out is really the fact that we have quite a bit of sales to iran in the first quarter of last year we also had some in the second quart